Working… Menu

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome (HERA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02855268
Recruitment Status : Recruiting
First Posted : August 4, 2016
Last Update Posted : November 19, 2021
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 4, 2023
Estimated Study Completion Date : December 4, 2023